Steiermaerkische Krankenanstalten Ges.m.b.H.
- Address
- Vordernberger Strasse 42, 8700 Leoben, Austria
Steiermaerkische Krankenanstalten Ges.m.b.H. - Comprehensive Cancer and Cardiovascular Research Center
Steiermaerkische Krankenanstalten Ges.m.b.H. is a leading medical research institution with extensive expertise in oncology and hematology clinical trials. The center specializes in advanced therapeutic approaches for various malignancies, with particular emphasis on breast cancer, lymphomas, and multiple myeloma, conducting pivotal phase II and III studies that contribute to advancing treatment standards in cancer care.
- Breast Cancer: Adjuvant and early-stage hormone receptor-positive and HER2-negative breast cancer trials investigating novel endocrine therapies and targeted agents
- Hematologic Malignancies: Comprehensive research in multiple myeloma, Hodgkin and non-Hodgkin lymphomas (including follicular and diffuse large B-cell lymphoma), chronic lymphocytic leukemia, acute myeloid leukemia, and myelofibrosis
- Ovarian Cancer: Studies evaluating maintenance therapy strategies in epithelial ovarian cancer
- Cardiovascular Disease: Biomarker-driven risk management studies for secondary prevention in acute myocardial infarction patients
The center demonstrates particular strength in evaluating novel immunotherapies, including bispecific antibodies and monoclonal antibodies, as well as combination treatment strategies involving targeted therapies, chemotherapy, and immunomodulatory agents. With active participation in international collaborative trials, the institution focuses on both treatment optimization and reduced toxicity approaches, particularly for elderly patients and those with high-risk disease features, while also incorporating advanced minimal residual disease (MRD) monitoring in hematologic malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 49 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 49 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1Medical University Of Graz3active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Medical University Of Graz3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Steiermaerkische Krankenanstalten Ges.m.b.H.
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Open-Label, Randomized Study To Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Combined with Chemotherapy versus Rituximab Combined with Chemotherapy in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-2) | Regeneron Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 49 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Doxorubicin Hydrochloride | 3 | Unknown | 2016-07-15 | 2024-06-03 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.